Andere Sprachen Genmab A/S

Aktien

565131

DK0010272202

GMAB

Biotechnologie

Markt geschlossen - Nasdaq Copenhagen Andere Börsenplätze 17:20:00 12.06.2026			% 5 Tage	Veränd. 1. Jan.
1 619,00 ^DKK	+0,15 %		+2,24 %	-20,13 %

11.06.	Genmab: Subgruppen-Daten zur Behandlung von follikulärem Lymphom belegen „nachhaltige“ Wirksamkeit	MT
11.06.	Genmab A/S präsentiert Subgruppendaten der EPCORE FL-1-Studie: Epcoritamab in Kombination mit Rituximab und Lenalidomid (R2) zeigt konsistente Wirksamkeit und Sicherheit bei rezidiviertem oder refraktärem follikulärem Lymphom	CI

Andere Sprachen

13.06.	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
13.06.	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
11.06.	Grant of Restricted Stock Units and Warrants to Employees in Genmab
11.06.	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits
11.06.	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
11.06.	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
11.06.	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients
09.06.	La Chine approuve le Tivdak de Pfizer dans le cancer du col de l'utérus
02.06.	U.S. Futures Slip, European Stocks Edge Up
01.06.	U.S. Futures Edge Up, European Stocks Mixed
29.05.	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
22.05.	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2026 Congress
21.05.	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
21.05.	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
18.05.	Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts
13.05.	Genmab A/S : Articles of association dated May 12, 2026 – English
13.05.	Genmab A/S : has published its Articles of Association
12.05.	Capital Increase in Genmab as a Result of Employee Warrant Exercise
11.05.	Genmab - Major Shareholder Announcement
11.05.	Genmab se reprend grâce à UBS
09.05.	Genmab: Market mispricing creates opportunity as good Q1 reinforces investment thesis
08.05.	Genmab says Orbis Investment Management Limited holds 5.08% of Genmab A/S as of May 8, 2026
08.05.	Major Shareholder Announcement
07.05.	Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2026
07.05.	Genmab Q1 Net Profit Falls, Revenue Rises